Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
|
|
Frazier Lifesciences Acquisition Corp
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/23/2022 |
8-K
| Appointed a new director|
Docs:
|
"Amended and Restated Memorandum and Articles of Association of the Surviving Company",
"Certificate of Incorporation of Frazier Lifesciences Acquisition Corporation",
"Bylaws of Frazier Lifesciences Acquisition Corporation",
"Warrant Assignment, Assumption and Amendment Agreement, between Continental Stock Transfer & Trust Company, NewAmsterdam Pharma Company B.V. and Frazier Lifesciences Acquisition Corporation",
"NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients" |
|
|
|